Last reviewed · How we verify
Two policies of iron prophylaxis
Two policies of iron prophylaxis is a Mineral supplement / Nutritional agent Small molecule drug developed by National Istitute For Health and Welfare, Finland. It is currently FDA-approved for Iron deficiency prevention in pregnant women, Iron deficiency prevention in infants and young children, Iron deficiency prevention in populations at risk of anemia.
Iron prophylaxis policies provide supplemental iron to prevent iron deficiency anemia in at-risk populations.
Iron prophylaxis policies provide supplemental iron to prevent iron deficiency anemia in at-risk populations. Used for Iron deficiency prevention in pregnant women, Iron deficiency prevention in infants and young children, Iron deficiency prevention in populations at risk of anemia.
At a glance
| Generic name | Two policies of iron prophylaxis |
|---|---|
| Sponsor | National Istitute For Health and Welfare, Finland |
| Drug class | Mineral supplement / Nutritional agent |
| Modality | Small molecule |
| Therapeutic area | Hematology / Preventive Medicine / Public Health |
| Phase | FDA-approved |
Mechanism of action
Iron prophylaxis involves the administration of iron supplements (typically ferrous salts or iron compounds) to individuals at high risk of iron deficiency, such as pregnant women, infants, or those with chronic blood loss. These policies aim to maintain adequate iron stores and hemoglobin levels, preventing the development of iron deficiency anemia and its associated complications including impaired cognitive development, reduced work capacity, and increased infection risk.
Approved indications
- Iron deficiency prevention in pregnant women
- Iron deficiency prevention in infants and young children
- Iron deficiency prevention in populations at risk of anemia
Common side effects
- Gastrointestinal upset (nausea, constipation, abdominal discomfort)
- Dark stools
- Metallic taste
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Two policies of iron prophylaxis CI brief — competitive landscape report
- Two policies of iron prophylaxis updates RSS · CI watch RSS
- National Istitute For Health and Welfare, Finland portfolio CI
Frequently asked questions about Two policies of iron prophylaxis
What is Two policies of iron prophylaxis?
How does Two policies of iron prophylaxis work?
What is Two policies of iron prophylaxis used for?
Who makes Two policies of iron prophylaxis?
What drug class is Two policies of iron prophylaxis in?
What development phase is Two policies of iron prophylaxis in?
What are the side effects of Two policies of iron prophylaxis?
Related
- Drug class: All Mineral supplement / Nutritional agent drugs
- Manufacturer: National Istitute For Health and Welfare, Finland — full pipeline
- Therapeutic area: All drugs in Hematology / Preventive Medicine / Public Health
- Indication: Drugs for Iron deficiency prevention in pregnant women
- Indication: Drugs for Iron deficiency prevention in infants and young children
- Indication: Drugs for Iron deficiency prevention in populations at risk of anemia
- Compare: Two policies of iron prophylaxis vs similar drugs
- Pricing: Two policies of iron prophylaxis cost, discount & access